VWR Corporation (NASDAQ: VWR) and CryoLife (NYSE:CRY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Volatility & Risk

VWR Corporation has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, CryoLife has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for VWR Corporation and CryoLife, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VWR Corporation 0 3 1 0 2.25
CryoLife 0 0 3 0 3.00

VWR Corporation currently has a consensus price target of $29.00, suggesting a potential downside of 12.49%. CryoLife has a consensus price target of $22.33, suggesting a potential downside of 1.62%. Given CryoLife’s stronger consensus rating and higher possible upside, analysts clearly believe CryoLife is more favorable than VWR Corporation.

Profitability

This table compares VWR Corporation and CryoLife’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VWR Corporation 3.12% 15.54% 4.69%
CryoLife 6.16% 7.41% 4.95%

Institutional and Insider Ownership

68.9% of CryoLife shares are owned by institutional investors. 35.5% of VWR Corporation shares are owned by company insiders. Comparatively, 6.0% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares VWR Corporation and CryoLife’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
VWR Corporation $4.58 billion 0.95 $492.10 million $1.08 30.69
CryoLife $183.16 million 4.15 $23.56 million $0.33 68.79

VWR Corporation has higher revenue and earnings than CryoLife. VWR Corporation is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Summary

CryoLife beats VWR Corporation on 8 of the 14 factors compared between the two stocks.

VWR Corporation Company Profile

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.

CryoLife Company Profile

CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.

Receive News & Stock Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related stocks with our FREE daily email newsletter.